BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 18385267)

  • 1. New insights into the function of the Wilms tumor suppressor gene WT1 in podocytes.
    Morrison AA; Viney RL; Saleem MA; Ladomery MR
    Am J Physiol Renal Physiol; 2008 Jul; 295(1):F12-7. PubMed ID: 18385267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the phenotypic variation due to the Denys-Drash syndrome-associated germline WT1 mutation R362X.
    Heathcott RW; Morison IM; Gubler MC; Corbett R; Reeve AE
    Hum Mutat; 2002 Apr; 19(4):462. PubMed ID: 11933209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small glomeruli in WAGR (Wilms Tumor, Aniridia, Genitourinary Anomalies and Mental Retardation) syndrome.
    Dahan K; Kamal M; Noël LH; Jeanpierre C; Gubler MC; Brousse N; Mariaud de Serre NP
    Am J Kidney Dis; 2007 Jun; 49(6):793-800. PubMed ID: 17533022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis.
    Patek CE; Fleming S; Miles CG; Bellamy CO; Ladomery M; Spraggon L; Mullins J; Hastie ND; Hooper ML
    Hum Mol Genet; 2003 Sep; 12(18):2379-94. PubMed ID: 12915483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
    Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
    Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis.
    Yang Y; Jeanpierre C; Dressler GR; Lacoste M; Niaudet P; Gubler MC
    Am J Pathol; 1999 Jan; 154(1):181-92. PubMed ID: 9916932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor splice-site mutations in WT1 are responsible for Frasier syndrome.
    Barbaux S; Niaudet P; Gubler MC; Grünfeld JP; Jaubert F; Kuttenn F; Fékété CN; Souleyreau-Therville N; Thibaud E; Fellous M; McElreavey K
    Nat Genet; 1997 Dec; 17(4):467-70. PubMed ID: 9398852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wilms tumor and the WT1 gene.
    Lee SB; Haber DA
    Exp Cell Res; 2001 Mar; 264(1):74-99. PubMed ID: 11237525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Müllerian-inhibiting substance, and the androgen receptor.
    Shimamura R; Fraizer GC; Trapman J; Lau YfC ; Saunders GF
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2571-80. PubMed ID: 9815658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: WT1 exon 6 truncation mutation and ambiguous genitalia in a patient with Denys-Drash syndrome.
    Chiang PW; Aliaga S; Travers S; Spector E; Tsai AC
    Curr Opin Pediatr; 2008 Feb; 20(1):103-6. PubMed ID: 18197048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome.
    Schumacher VA; Jeruschke S; Eitner F; Becker JU; Pitschke G; Ince Y; Miner JH; Leuschner I; Engers R; Everding AS; Bulla M; Royer-Pokora B
    J Am Soc Nephrol; 2007 Mar; 18(3):719-29. PubMed ID: 17267748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wilms' tumor suppressor gene WT1: from structure to renal pathophysiologic features.
    Mrowka C; Schedl A
    J Am Soc Nephrol; 2000 Nov; 11 Suppl 16():S106-15. PubMed ID: 11065340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into the physiological role of WT1 from studies of genetically modified mice.
    Discenza MT; Pelletier J
    Physiol Genomics; 2004 Feb; 16(3):287-300. PubMed ID: 14966251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mutant form of the Wilms' tumor suppressor gene WT1 observed in Denys-Drash syndrome interferes with glomerular capillary development.
    Natoli TA; Liu J; Eremina V; Hodgens K; Li C; Hamano Y; Mundel P; Kalluri R; Miner JH; Quaggin SE; Kreidberg JA
    J Am Soc Nephrol; 2002 Aug; 13(8):2058-67. PubMed ID: 12138137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of Cistromic and Transcriptomic Analyses Identifies Nphs2, Mafb, and Magi2 as Wilms' Tumor 1 Target Genes in Podocyte Differentiation and Maintenance.
    Dong L; Pietsch S; Tan Z; Perner B; Sierig R; Kruspe D; Groth M; Witzgall R; Gröne HJ; Platzer M; Englert C
    J Am Soc Nephrol; 2015 Sep; 26(9):2118-28. PubMed ID: 25556170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Aspects of WT1 and the Kidney.
    Miller-Hodges E
    Methods Mol Biol; 2016; 1467():15-21. PubMed ID: 27417956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of Wilms' tumor genes.
    Hirose M
    J Med Invest; 1999 Aug; 46(3-4):130-40. PubMed ID: 10687307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An unusual phenotype of Frasier syndrome due to IVS9 +4C>T mutation in the WT1 gene: predominantly male ambiguous genitalia and absence of gonadal dysgenesis.
    Melo KF; Martin RM; Costa EM; Carvalho FM; Jorge AA; Arnhold IJ; Mendonca BB
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2500-5. PubMed ID: 12050205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wilms' tumor protein Wt1 is an activator of the anti-Müllerian hormone receptor gene Amhr2.
    Klattig J; Sierig R; Kruspe D; Besenbeck B; Englert C
    Mol Cell Biol; 2007 Jun; 27(12):4355-64. PubMed ID: 17420277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel WT1 gene mutation in a newborn infant diagnosed with Denys-Drash syndrome.
    Hakan N; Aydin M; Erdogan O; Cavusoglu YH; Aycan Z; Ozaltin F; Zenciroglu A; Apaydin S; Gunes R; Sahin G; Cinar G; Okumus N
    Genet Couns; 2012; 23(2):255-61. PubMed ID: 22876585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.